In the past few years, new therapies shown to slow the progression of Alzheimer's disease in people in the early stages of the disease have been making their way through the U.S. Food and Drug Administration’s (FDA) approval process. With these treatments now available, there are a growing number of questions surrounding who is eligible to take these medications and what processes are needed to ensure they are prescribed safely and effectively. Host Dr. Nathaniel Chin examines the guidelines for geriatricians and clinicians prescribing lecanemab and breaks down the eligibility requirements necessary to receive this treatment.

Read Eisai/Biogen’s “Prescribing Information” for Leqembi online.

Read “Lecanemab: Appropriate Use Recommendations” on the National Library of Medicine website.

Read the U.S. Department of Veterans Affairs’ (VA) guidelines for prescribing lecanemab, “Lecanemab-irmb (LEQEMBI) Criteria for Use August 2023,'' online.

Listen to previous Dementia Matters episodes on lecanemab, including “Putting Lecanemab into Practice: A Clinician’s Perspective on the New Alzheimer’s Treatment,” “A Closer Look at the Lecanemab Clinical Trials,” and “Introducing Lecanemab, The Latest Alzheimer’s Disease Drug to Receive FDA Accelerated Approval,” on our website and all major podcast platforms.

Find transcripts and more at our website.

Email Dementia Matters: [email protected]

Follow us on Facebook and Twitter.

Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.